Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25589865 | 0.94 | CCR2 (0.47) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL21843787 | 0.94 | CCR2 (0.47) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL25589896 | 0.94 | CCR2 (0.47) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL9963367 | 0.88 | CCR2 (0.41) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL14703898 | 0.84 | HTT (0.52) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL3008085 | 0.80 | CCR2 (0.53) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL8358035 | 0.80 | CCR2 (0.53) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL2778896 | 0.80 | CCR2 (0.53) | CCR2HTTRAB9AMMP1MMP3 | |
| SCHEMBL8459922 | 0.80 | CCR2 (0.57) | CCR2HTTRAB9ANPC1 | |
| SCHEMBL327869 | 0.80 | CCR2 (0.57) | CCR2HTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416111-B2 | Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-18 | — | — | US | disclosed |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | CASH BRANDON (US) | 2013-02-14 | — | — | US | disclosed |
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARSHAKOON NAMAL CHITHRANGA (US) | 2012-05-10 | — | — | US | disclosed |
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARNER CHILCOTT COMPANY, LLC | 2010-12-02 | — | — | US | disclosed |
| US-7790748-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-7247648-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | CCR2 451/4885HTT 4198/4885RAB9A 2496/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | CCR2 483/4885HTT 4317/4885RAB9A 2641/4885 |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, CD4 | CCR2 452/4885HTT 3971/4885RAB9A 2717/4885 |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | CCR2 451/4885HTT 4198/4885RAB9A 2496/4885 |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CCR2 3479/4885HTT 2241/4885RAB9A 2835/4885 |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | SYK, ZAP70, TYRO3 | CCR2 519/4885HTT 3281/4885RAB9A 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.